P384: The usefulness of salazosulfapyridine for
patients with ulcerative colitis refractory to mesalazineECCO '16 Amsterdam
2016
P385: Predictors of tissue healing in ulcerative colitis patients treated with anti-TNFECCO '16 Amsterdam
2016
P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in GermanyECCO '16 Amsterdam
2016
P387: Does standard therapy in paediatric Crohn’s disease really prevent our patients from the need of early initiation of anti-TNF treatment?ECCO '16 Amsterdam
2016
P388: Clinical care pathways are needed to decrease variability in the management of the hospitalised ulcerative colitis patientECCO '16 Amsterdam
2016
P389: The value of oxidative stress parameters to predict histological severity in ulcerative colitisECCO '16 Amsterdam
2016
P390: To double dose or not to double dose? That is the question: Single centre experience in the use of infliximab antibodies and levels in a paediatric IBD (pIBD) cohortECCO '16 Amsterdam
2016
P391: Gender differences in adalimumab continuation rates: Results of a Crohn’s disease cohortECCO '16 Amsterdam
2016
P393: Investigation of Crohn’s disease patients receiving anti-TNF α therapy after surgery for intestinal stenosisECCO '16 Amsterdam
2016
P394: Psychosexual dysfunction in a cohort of Greek inflammatory bowel disease patients in clinical remission: preliminary resultsECCO '16 Amsterdam
2016
P395: Real-life prospective experience with adalimumab in ulcerative colitis in Italy: preliminary results of a pilot studyECCO '16 Amsterdam
2016
P396: Cyclosporin A efficacy in a paediatric ulcerative colitis: a retrospective single-centre studyECCO '16 Amsterdam
2016
P397: Efficacy and safety of sequential rescue therapy with infliximab and tacrolimus in patients with corticosteroid-refractory ulcerative colitisECCO '16 Amsterdam
2016
P398: The costs of care for patients with ulcerative colitis: effect of adalimumab on health care resources utilisation in clinical practice from INSPIRADAECCO '16 Amsterdam
2016
P400: Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort StudyECCO '16 Amsterdam
2016